NRG-GY006 – a randomized phase II trial of radiation therapy and
cisplatin alone or in combination with intravenous tripine in women with
newly diagnosed bulky stage IB2, stage II, IIIB, or IVA cancer of the
uterine cervix or stage II-IVA vaginal cancer.
What type of cancer? What stage?
Cervix or vaginal cancer.
Who is eligible?
Women who will be treated with radiation.
How will I be treated?
Patients will be randomized to receive Triapine, along with standard curative
therapy. Tripine is a biologic drug, a ribonucleotide reductase inhibitor.
For physicians: more information about this specific trial at
clinicaltrials.gov.
